NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors

Restricted access

The standard of care for managing patients with gastrointestinal stromal tumors (GISTs) rapidly changed after the introduction of effective molecularly targeted therapies involving tyrosine kinase inhibitors (TKIs), such as imatinib mesylate and sunitinib malate. A better understanding of the molecular characteristics of GISTs have improved the diagnostic accuracy and led to the discovery of novel immunomarkers and new mechanisms of resistance to TKI therapy, which in turn have resulted in the development of novel treatment strategies. To address these issues, the NCCN organized a task force consisting of a multidisciplinary panel of experts in the fields of medical oncology, surgical oncology, molecular diagnostics, and pathology to discuss the recent advances, identify areas of future research, and recommend an optimal approach to care for patients with GIST at all stages of disease. The task force met for the first time in October 2003 and again in December 2006 and October 2009. This supplement describes the recent developments in the field of GIST as discussed at the October 2009 meeting.

  • 1

    NishidaTHirotaS. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol2000;15:12931301.

    • Search Google Scholar
    • Export Citation
  • 2

    ThomasRMSobinLH. Gastrointestinal cancer. Cancer1995;75:154170.

  • 3

    TranTDavilaJAEl-SeragHB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol2005;100:162168.

    • Search Google Scholar
    • Export Citation
  • 4

    TryggvasonGGislasonHGMagnussonMK. Gastrointestinal stromal tumors in Iceland, 1990-2003: the Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer2005;117:289293.

    • Search Google Scholar
    • Export Citation
  • 5

    GoettschWGBosSDBreekveldt-PostmaN. Incidence of gastrointestinal stromal tumors is underestimated: results of a nation-wide study. Eur J Cancer2005;41:28682872.

    • Search Google Scholar
    • Export Citation
  • 6

    RubioJMarcos-GrageraROrtizMR. Population-based incidence and survival of gastrointestinal stromal tumors (GIST) in Girona, Spain. Eur J Cancer2007;43:144148.

    • Search Google Scholar
    • Export Citation
  • 7

    NilssonBBummingPMeis-KindblomJM. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden. Cancer2005;103:821829.

    • Search Google Scholar
    • Export Citation
  • 8

    PerezEALivingstoneASFranceschiD. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg2006;202:623629.

    • Search Google Scholar
    • Export Citation
  • 9

    SteigenSEEideTJ. Trends in the incidence and survival of mesenchymal neoplasm of the digestive tract within a defined population of northern Norway. APMIS2006;114:192200.

    • Search Google Scholar
    • Export Citation
  • 10

    AgaimyAWunschPHHofstaedterF. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol2007;31:113120.

    • Search Google Scholar
    • Export Citation
  • 11

    MiettinenMSobinLHLasotaJ. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol2005;29:5268.

    • Search Google Scholar
    • Export Citation
  • 12

    MiettinenMMakhloufHSobinLH. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol2006;30:477489.

    • Search Google Scholar
    • Export Citation
  • 13

    MiettinenMLasotaJ. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol2006;23:7083.

  • 14

    MiettinenMLasotaJ. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med2006;130:14661478.

    • Search Google Scholar
    • Export Citation
  • 15

    ReithJDGoldblumJRLylesRHWeissSW. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol2000;13:577585.

    • Search Google Scholar
    • Export Citation
  • 16

    DeMatteoRPLewisJJLeungD. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg2000;231:5158.

    • Search Google Scholar
    • Export Citation
  • 17

    van der ZwanSMDeMatteoRP. Gastrointestinal stromal tumor: 5 years later. Cancer2005;104:17811788.

  • 18

    SepePSBruggeWR. A guide for the diagnosis and management of gastrointestinal stromal cell tumors. Nat Rev Gastroenterol Hepatol2009;6:363371.

    • Search Google Scholar
    • Export Citation
  • 19

    FletcherCDBermanJJCorlessC. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol2002;33:459465.

  • 20

    ChirieacLRTrentJCSteinertDM. Correlation of immunophenotype with PFS in patients with gastrointestinal stromal tumors treated with imatinib mesylate. Cancer2006;107:22372244.

    • Search Google Scholar
    • Export Citation
  • 21

    MiettinenMLasotaJ. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol2005;13:205220.

    • Search Google Scholar
    • Export Citation
  • 22

    MiettinenMSobinLHSarlomo-RikalaM. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol2000;13:11341142.

    • Search Google Scholar
    • Export Citation
  • 23

    Debiec-RychterMWasagBStulM. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol2004;202:430438.

    • Search Google Scholar
    • Export Citation
  • 24

    MedeirosFCorlessCLDuensingA. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol2004;28:889894.

    • Search Google Scholar
    • Export Citation
  • 25

    HeinrichMCCorlessCLDuensingA. PDGFRA activating mutations in gastrointestinal stromal tumors. Science2003;299:708710.

  • 26

    HirotaSOhashiANishidaT. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology2003;125:660667.

    • Search Google Scholar
    • Export Citation
  • 27

    CorlessCLSchroederAGriffithD. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol2005;23:53575364.

    • Search Google Scholar
    • Export Citation
  • 28

    RossiGValliRBertoliniF. PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumours and other primary soft-tissue tumours of the gastrointestinal tract. Histopathology2005;46:522531.

    • Search Google Scholar
    • Export Citation
  • 29

    MiselliFMillefantiCConcaE. PDGFRA immunostaining can help in the diagnosis of gastrointestinal stromal tumors. Am J Surg Pathol2008;32:738743.

    • Search Google Scholar
    • Export Citation
  • 30

    PetersonMRPiaoZWeidnerNYiES. Strong PDGFRA positivity is seen in GISTs but not in other intra-abdominal mesenchymal tumors: immunohistochemical and mutational analyses. Appl Immunohistochem Mol Morphol2006;14:390396.

    • Search Google Scholar
    • Export Citation
  • 31

    AgaramNPWongGCGuoT. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer2008;47:853859.

    • Search Google Scholar
    • Export Citation
  • 32

    DuensingAJosephNEMedeirosF. Protein kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res2004;64:51275131.

    • Search Google Scholar
    • Export Citation
  • 33

    KimKMKangDWMoonWS. PKCtheta expression in gastrointestinal stromal tumor. Mod Pathol2006;19:14801486.

  • 34

    OuWbZhuMjDemetriGD. Protein kinase C-[theta] regulates KIT expression and proliferation in gastrointestinal stromal tumors. Oncogene2008;27:56245634.

    • Search Google Scholar
    • Export Citation
  • 35

    WestRBCorlessCLChenX. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol2004;165:107113.

    • Search Google Scholar
    • Export Citation
  • 36

    EspinosaILeeCHKimMK. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol2008;32:210218.

    • Search Google Scholar
    • Export Citation
  • 37

    MiettinenMWangZFLasotaJ. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol2009;33:14011408.

    • Search Google Scholar
    • Export Citation
  • 38

    LieglBHornickJLCorlessCLFletcherCD. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol2009;33:437446.

    • Search Google Scholar
    • Export Citation
  • 39

    NielsenTOWestRBLinnSC. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet2002;359:13011307.

  • 40

    AntonescuCRVialeASarranL. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res2004;10:32823290.

    • Search Google Scholar
    • Export Citation
  • 41

    SegalNHPavlidisPAntonescuCR. Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol2003;163:691700.

    • Search Google Scholar
    • Export Citation
  • 42

    SubramanianSWestRBCorlessCL. Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene2004;23:77807790.

    • Search Google Scholar
    • Export Citation
  • 43

    PantaleoMAAstolfiADi BattistaM. Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target. Int J Cancer2009;125:29912994.

    • Search Google Scholar
    • Export Citation
  • 44

    AgaramNPLaquagliaMPUstunB. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res2008;14:32043215.

    • Search Google Scholar
    • Export Citation
  • 45

    AgaramNPBesmerPWongGC. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res2007;13:170181.

    • Search Google Scholar
    • Export Citation
  • 46

    MiettinenMLasotaJ. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch2001;438:112.

    • Search Google Scholar
    • Export Citation
  • 47

    DematteoRPGoldJSSaranL. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer2008;112:608615.

    • Search Google Scholar
    • Export Citation
  • 48

    GoldJSGonenMGutierrezA. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol2009;10:10451052.

    • Search Google Scholar
    • Export Citation
  • 49

    SeidalTEdvardssonH. Expression of c-kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumours. Histopathology1999;34:416424.

    • Search Google Scholar
    • Export Citation
  • 50

    SaponaraMDi BattistaMLolliC. Evaluation of Ki-67 in gastrointestinal stromal tumor (GIST) [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract e21510.

    • Search Google Scholar
    • Export Citation
  • 51

    LasotaJMiettinenM. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology2008;53:245266.

    • Search Google Scholar
    • Export Citation
  • 52

    LasotaJCorlessCLHeinrichMC. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol2008;21:476484.

    • Search Google Scholar
    • Export Citation
  • 53

    McAuliffeJCWangWLPavanGM. Unlucky number 13? Differential effects of KIT exon 13 mutation in gastrointestinal stromal tumors. Mol Oncol2008;2:161163.

    • Search Google Scholar
    • Export Citation
  • 54

    TarnCRinkLMerkelE. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A2008;105:83878392.

    • Search Google Scholar
    • Export Citation
  • 55

    BelinskyMGRinkLCaiKQ. The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors. Cell Cycle2008;7:29492955.

    • Search Google Scholar
    • Export Citation
  • 56

    BraconiCBracciRBearziI. Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Ann Oncol2008;19:12931298.

    • Search Google Scholar
    • Export Citation
  • 57

    SingerSRubinBPLuxML. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol2002;20:38983905.

    • Search Google Scholar
    • Export Citation
  • 58

    KimTWLeeHKangYK. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res2004;10:30763081.

    • Search Google Scholar
    • Export Citation
  • 59

    AnderssonJBummingPMeis-KindblomJM. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology2006;130:15731581.

    • Search Google Scholar
    • Export Citation
  • 60

    RubinBPSingerSTsaoC. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res2001;61:81188121.

  • 61

    CorlessCLMcGreeveyLHaleyA. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol2002;160:15671572.

    • Search Google Scholar
    • Export Citation
  • 62

    LasotaJDansonka-MieszkowskaAStachuraT. Gastrointestinal stromal tumors with internal tandem duplications in 3’ end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course. Mod Pathol2003;16:12571264.

    • Search Google Scholar
    • Export Citation
  • 63

    MartinJPovedaALlombart-BoschA. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol2005;23:61906198.

    • Search Google Scholar
    • Export Citation
  • 64

    AntonescuCRSommerGSarranL. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res2003;9:33293337.

    • Search Google Scholar
    • Export Citation
  • 65

    LasotaJDansonka-MieszkowskaASobinLH. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest2004;84:874883.

    • Search Google Scholar
    • Export Citation
  • 66

    LasotaJStachuraJMiettinenM. GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology. Lab Invest2006;86:94100.

    • Search Google Scholar
    • Export Citation
  • 67

    HeinrichMCCorlessCLDemetriGD. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol2003;21:43424349.

    • Search Google Scholar
    • Export Citation
  • 68

    Debiec-RychterMDumezHJudsonI. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer2004;40:689695.

    • Search Google Scholar
    • Export Citation
  • 69

    Debiec-RychterMSciotRLe CesneA. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer2006;42:10931103.

    • Search Google Scholar
    • Export Citation
  • 70

    HeinrichMCOwzarKCorlessCL. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol2008;26:53605367.

    • Search Google Scholar
    • Export Citation
  • 71

    Gastrointestinal Stromal Tumor Meta-Analysis Group. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1640 patients. J Clin Oncol2010;28:12471253.

    • Search Google Scholar
    • Export Citation
  • 72

    HeinrichMCMakiRGCorlessCL. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol2008;26:53525359.

    • Search Google Scholar
    • Export Citation
  • 73

    BlankeCDCorlessCL. State-of-the art therapy for gastrointestinal stromal tumors. Cancer Invest2005;23:274280.

  • 74

    RyanDPPuchalskiTSupkoJG. A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist2002;7:531538.

    • Search Google Scholar
    • Export Citation
  • 75

    EdmonsonJHMarksRSBucknerJCMahoneyMR. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest2002;20:605612.

    • Search Google Scholar
    • Export Citation
  • 76

    TrentJCBeachJBurgessMA. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer2003;98:26932699.

    • Search Google Scholar
    • Export Citation
  • 77

    DemetriGDvon MehrenMBlankeCD. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med2002;347:472480.

    • Search Google Scholar
    • Export Citation
  • 78

    HeinrichMCGriffithDJDrukerBJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood2000;96:925932.

    • Search Google Scholar
    • Export Citation
  • 79

    BuchdungerECioffiCLLawN. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther2000;295:139145.

    • Search Google Scholar
    • Export Citation
  • 80

    TuvesonDAWillisNAJacksT. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene2001;20:50545058.

    • Search Google Scholar
    • Export Citation
  • 81

    DrukerBJTamuraSBuchdungerE. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med1996;2:561566.

    • Search Google Scholar
    • Export Citation
  • 82

    JoensuuHRobertsPJSarlomo-RikalaM. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med2001;344:10521056.

    • Search Google Scholar
    • Export Citation
  • 83

    DagherRCohenMWilliamsG. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res2002;8:30343038.

    • Search Google Scholar
    • Export Citation
  • 84

    BlankeCDDemetriGDvon MehrenM. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol2008;26:620625.

    • Search Google Scholar
    • Export Citation
  • 85

    van OosteromATJudsonIVerweijJ. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet2001;358:14211423.

    • Search Google Scholar
    • Export Citation
  • 86

    VerweijJvan OosteromABlayJY. Imatinib mesylate (STI571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer2003;39:20062011.

    • Search Google Scholar
    • Export Citation
  • 87

    BlankeCDRankinCDemetriGD. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol2008;26:626632.

    • Search Google Scholar
    • Export Citation
  • 88

    VerweijJCasaliPGZalcbergJ. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet2004;364:11271134.

    • Search Google Scholar
    • Export Citation
  • 89

    ZalcbergJRVerweijJCasaliPG. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer2005;41:17511757.

    • Search Google Scholar
    • Export Citation
  • 90

    WidmerNDecosterdLALeyvrazS. Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer2008;98:16331640.

    • Search Google Scholar
    • Export Citation
  • 91

    DelbaldoCChatelutEReM. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res2006;12:60736078.

    • Search Google Scholar
    • Export Citation
  • 92

    DemetriGDWangYWehrleE. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol2009;27:31413147.

    • Search Google Scholar
    • Export Citation
  • 93

    GuilhotF. Indications for imatinib mesylate therapy and clinical management. Oncologist2004;9:271281.

  • 94

    FerreroDPoglianiEMRege-CambrinG. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica2006;91:ECR27.

  • 95

    GanjooKNDemetriGDJacobsCPatelS. Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec. Leuk Lymphoma2009;50:18821884.

    • Search Google Scholar
    • Export Citation
  • 96

    BermanENicolaidesMMakiRG. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med2006;354:20062013.

    • Search Google Scholar
    • Export Citation
  • 97

    JoensuuHReichardtP. Imatinib and altered bone and mineral metabolism [letter]. N Eng J Med2006;355;627628.

  • 98

    KerkelaRGrazetteLYacobiR. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Med2006;12:881882.

  • 99

    TrentJCPatelSSZhangJ. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer2009;116:184192.

    • Search Google Scholar
    • Export Citation
  • 100

    QuekRMorganJAGeorgeS. Small molecule tyrosine kinase inhibitor and depression. J Clin Oncol2009;27:312313.

  • 101

    BenjaminRSDebiec-RychterMLe CesneA. Gastrointestinal stromal tumors II: medical oncology and tumor response assessment. Semin Oncol2009;36:302311.

    • Search Google Scholar
    • Export Citation
  • 102

    MaledduAPantaleoMANanniniM. Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (review). Oncol Rep2009;21:13591366.

    • Search Google Scholar
    • Export Citation
  • 103

    ChenLLTrentJCWuEF. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res2004;64:59135919.

    • Search Google Scholar
    • Export Citation
  • 104

    AntonescuCRBesmerPGuoT. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res2005;11:41824190.

    • Search Google Scholar
    • Export Citation
  • 105

    Debiec-RychterMCoolsJDumezH. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology2005;128:270279.

    • Search Google Scholar
    • Export Citation
  • 106

    HeinrichMCCorlessCLBlankeCD. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol2006;24:47644774.

    • Search Google Scholar
    • Export Citation
  • 107

    WardelmannEMerkelbach-BruseSPaulsK. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res2006;12:17431749.

    • Search Google Scholar
    • Export Citation
  • 108

    LieglBKeptenILeC. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol2008;216:6474.

  • 109

    BurgerHNooterK. Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib. Cell Cycle2004;3:15021505.

    • Search Google Scholar
    • Export Citation
  • 110

    BurgerHvan TolHBrokM. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther2005;4:747752.

    • Search Google Scholar
    • Export Citation
  • 111

    DemetriGDvan OosteromATGarrettCR. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet2006;368:13291338.

    • Search Google Scholar
    • Export Citation
  • 112

    DemetriGDHuangXGarrettCR. Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 10524.

    • Search Google Scholar
    • Export Citation
  • 113

    GeorgeSBlayJYCasaliPG. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer2009;45:19591968.

    • Search Google Scholar
    • Export Citation
  • 114

    IzzedineHEderhySGoldwasserF. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol2009;20:807815.

  • 115

    ZhuXStergiopoulosKWuS. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol2009;48:917.

    • Search Google Scholar
    • Export Citation
  • 116

    AziziMChedidAOudardS. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med2008;358:9597.

  • 117

    ChuTFRupnickMAKerkelaR. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet2007;370:20112019.

  • 118

    BelloCLMulayMHuangX. Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic-pharmacodynamic evaluation of sunitinib. Clin Cancer Res2009;15:70457052.

    • Search Google Scholar
    • Export Citation
  • 119

    TorinoFCorselloSMLongoR. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol2009;6:219228.

    • Search Google Scholar
    • Export Citation
  • 120

    DesaiJYassaLMarquseeE. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med2006;145:660664.

    • Search Google Scholar
    • Export Citation
  • 121

    ChuDLacoutureMEWeinerEWuS. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer2009;7:1119.

    • Search Google Scholar
    • Export Citation
  • 122

    GajiwalaKSWuJCChristensenJ. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A2009;106:15421547.

    • Search Google Scholar
    • Export Citation
  • 123

    GuoTHajduMAgaramNP. Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer Res2009;15:68626870.

    • Search Google Scholar
    • Export Citation
  • 124

    KaoJPackerSVuHL. Phase I study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer2009;115:35713580.

    • Search Google Scholar
    • Export Citation
  • 125

    WiebeLKaszaKEMakiRG. Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): a phase II trial of the University of Chicago Phase II Consortium [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 10502.

    • Search Google Scholar
    • Export Citation
  • 126

    ReichardtPMontemurroMGelderblomH. Sorafenib fourth-line treatment in imatinib-, sunitinib-, and nilotinib-resistant metastatic GIST: a retrospective analysis [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 10564.

    • Search Google Scholar
    • Export Citation
  • 127

    DewaeleBWasagBCoolsJ. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor–associated PDGFRAD842V mutation. Clin Cancer Res2008;14:57495758.

    • Search Google Scholar
    • Export Citation
  • 128

    SchittenhelmMMShiragaSSchroederA. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res2006;66:473481.

    • Search Google Scholar
    • Export Citation
  • 129

    DemetriGDLo RussoPMacPhersonIR. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res2009;15:62326240.

    • Search Google Scholar
    • Export Citation
  • 130

    DemetriGDCasaliPGBlayJY. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res2009;15:59105916.

    • Search Google Scholar
    • Export Citation
  • 131

    MontemurroMSchoffskiPReichardtP. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer2009;45:22932297.

    • Search Google Scholar
    • Export Citation
  • 132

    BlayJYLe CesneARay-CoquardI. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol2007;25:11071113.

    • Search Google Scholar
    • Export Citation
  • 133

    FumagalliECocoPMorosiC. Rechallenge with imatinib in GIST patients resistant to second or third line therapy [abstract]. Presented at the 15th Annual CTOS Meeting; November 5–7, 2009; Miami Beach, Florida. Abstract 39404.

    • Search Google Scholar
    • Export Citation
  • 134

    OsterbergLBlaschkeT. Adherence to medication. N Engl J Med2005;353:487497.

  • 135

    NoensLvan LierdeMADe BockR. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood2009;113:54015411.

    • Search Google Scholar
    • Export Citation
  • 136

    DuffaudFRay-CoquardIBuiB. Time to secondary resistance (TSR) after interruption of imatinib: updated results of the prospective French Sarcoma Group randomized phase III trial on long-term survival [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 10508.

    • Search Google Scholar
    • Export Citation
  • 137

    FongYCoitDGWoodruffJM. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg1993;217:7277.

    • Search Google Scholar
    • Export Citation
  • 138

    NgEHPollockREMunsellMF. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg1992;215:6877.

    • Search Google Scholar
    • Export Citation
  • 139

    AkwariOEDozoisRRWeilandLH. Leiomyosarcoma of the small and large bowel. Cancer1978;42:13751384.

  • 140

    McGrathPCNeifeldJPLawrenceWJ. Gastrointestinal sarcomas. Analysis of prognostic factors. Ann Surg1987;206:706710.

  • 141

    KawanowaKSakumaYSakuraiS. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol2006;37:15271535.

  • 142

    AgaimyAWunschPHDirnhoferS. Microscopic gastrointestinal stromal tumors in esophageal and intestinal surgical resection specimens: a clinicopathologic, immunohistochemical, and molecular study of 19 lesions. Am J Surg Pathol2008;32:867873.

    • Search Google Scholar
    • Export Citation
  • 143

    ChettyR. Small and microscopically detected gastrointestinal stromal tumours: an overview. Pathology2008;40:912.

  • 144

    DavilaREFaigelDO. GI stromal tumors. Gastrointest Endosc2003;58:8088.

  • 145

    LokKHLaiLYiuHL. Endosonographic surveillance of small gastrointestinal tumors originating from muscularis propria. J Gastrointestin Liver Dis2009;18:177180.

    • Search Google Scholar
    • Export Citation
  • 146

    SunSGeNWangC. Endoscopic band ligation of small gastric stromal tumors and follow-up by endoscopic ultrasonography. Surg Endosc2007;21:574578.

    • Search Google Scholar
    • Export Citation
  • 147

    OtaniYKitajimaM. Laparoscopic surgery: too soon to decide. Gastric Cancer2005;8:135136.

  • 148

    NovitskyYWKercherKWSingRF. Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors. Ann Surg2006;243:738745; discussion 745–747.

    • Search Google Scholar
    • Export Citation
  • 149

    OtaniYFurukawaTYoshidaM. Operative indications for relatively small (2-5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases. Surgery2006;139:484492.

    • Search Google Scholar
    • Export Citation
  • 150

    NakamoriMIwahashiMNakamuraM. Laparoscopic resection for gastrointestinal stromal tumors of the stomach. Am J Surg2008;196:425429.

  • 151

    NishimuraJNakajimaKOmoriT. Surgical strategy for gastric gastrointestinal stromal tumors: laparoscopic vs. open resection. Surg Endosc2007;21:875878.

    • Search Google Scholar
    • Export Citation
  • 152

    HuguetKLRushRMJrTessierDJ. Laparoscopic gastric gastrointestinal stromal tumor resection: the mayo clinic experience. Arch Surg2008;143:587590.

    • Search Google Scholar
    • Export Citation
  • 153

    EisenbergBLHarrisJBlankeCD. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol2009;99:4247.

    • Search Google Scholar
    • Export Citation
  • 154

    McAuliffeJCHuntKKLazarAJ. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol2009;16:910919.

    • Search Google Scholar
    • Export Citation
  • 155

    BonvalotSEldwenyHPechouxCL. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol2006;13:15961603.

    • Search Google Scholar
    • Export Citation
  • 156

    HohenbergerPOladejiOLichtT. Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST) [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 10550.

    • Search Google Scholar
    • Export Citation
  • 157

    DeMatteoRPOwzarKAntonescuCR. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the U.S. Intergroup phase II trial ACOSOG Z9000 [abstract]. Preseneted at the 2008 ASCO Gastrointestinal Cancers Symposium; January 25–27, 2008; Orlando, Florida. Abstract 8.

    • Search Google Scholar
    • Export Citation
  • 158

    DeMatteoROwzarKMakiR. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001 [abstract]. Presented at the 43rd ASCO Annual Meeting; June 1–5, 2007; Chicago, Illinois. Abstract 10079.

    • Search Google Scholar
    • Export Citation
  • 159

    DematteoRPBallmanKVAntonescuCR. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, doubleblind, placebocontrolled trial. Lancet2009;373:10971104.

    • Search Google Scholar
    • Export Citation
  • 160

    ZhanWHChina Gastrointestinal Cooperative Group. Efficacy and safety of adjuvant post-surgical therapy with imatinib in patients with high risk of relapsing GIST [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 10045.

    • Search Google Scholar
    • Export Citation
  • 161

    LiJGongFJWuWAShenL. Adjuvant therapy with imatinib in gastrointestinal stromal tumor (GIST) patients with intermediate or high risk: analysis from a single-center contrast study [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 10556.

    • Search Google Scholar
    • Export Citation
  • 162

    ScaifeCLHuntKKPatelSR. Is there a role for surgery in patients with “unresectable” cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?Am J Surg2003;186:665669.

    • Search Google Scholar
    • Export Citation
  • 163

    BummingPAnderssonJMeis-KindblomJM. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer2003;89:460464.

    • Search Google Scholar
    • Export Citation
  • 164

    BauerSHartmannJTde WitM. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer2005;117:316325.

    • Search Google Scholar
    • Export Citation
  • 165

    RautCPPosnerMDesaiJ. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol2006;24:23252331.

    • Search Google Scholar
    • Export Citation
  • 166

    RutkowskiPNoweckiZNyckowskiP. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol2006;93:304311.

    • Search Google Scholar
    • Export Citation
  • 167

    AndtbackaRHNgCSScaifeCL. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol2007;14:1424.

    • Search Google Scholar
    • Export Citation
  • 168

    GronchiAFioreMMiselliF. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg2007;245:341346.

    • Search Google Scholar
    • Export Citation
  • 169

    DeMatteoRPMakiRGSingerS. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor (GIST). Ann Surg2007;245:347352.

    • Search Google Scholar
    • Export Citation
  • 170

    SymSJRyuMHLeeJL. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J Surg Oncol2008;98:2733.

    • Search Google Scholar
    • Export Citation
  • 171

    MussiCRonellenfitschUJakobJ. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?Ann Oncol2010;21:403408.

    • Search Google Scholar
    • Export Citation
  • 172

    RautCPWangQManolaJ. Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate. Ann Surg Oncol2010;17:407415.

    • Search Google Scholar
    • Export Citation
  • 173

    YeYJGaoZDPostonGJWangS. Diagnosis and multi-disciplinary management of hepatic metastases from gastrointestinal stromal tumour (GIST). Eur J Surg Oncol2009;35:787792.

    • Search Google Scholar
    • Export Citation
  • 174

    MaluccioMACoveyAMSchubertJ. Treatment of metastatic sarcoma to the liver with bland embolization. Cancer2006;107:16171623.

  • 175

    KobayashiKGuptaSTrentJC. Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors: response, survival, and prognostic factors. Cancer2006;107:28332841.

    • Search Google Scholar
    • Export Citation
  • 176

    AvritscherRGuptaS. Gastrointestinal stromal tumor: role of interventional radiology in diagnosis and treatment. Hematol Oncol Clin North Am2009;23:129137.

    • Search Google Scholar
    • Export Citation
  • 177

    PawlikTMVautheyJNAbdallaEK. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg2006;141:537543; discussion 543–534.

    • Search Google Scholar
    • Export Citation
  • 178

    SerraltaASSanjuanFRMoyaAH. Combined liver transplantation plus imatinib for unresectable metastases of gastrointestinal stromal tumours. Eur J Gastroenterol Hepatol2004;16:12371239.

    • Search Google Scholar
    • Export Citation
  • 179

    BenjaminRSChoiHMacapinlacHA. We should desist using RECIST, at least in GIST. J Clin Oncol2007;25:17601764.

  • 180

    Le CesneAVan GlabbekeMVerweijJ. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors rreated with imatinib mesylate: the Intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol2009;27:39693974.

    • Search Google Scholar
    • Export Citation
  • 181

    HoldsworthCHBadawiRDManolaJB. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR Am J Roentgenol2007;189:W324330.

    • Search Google Scholar
    • Export Citation
  • 182

    ChoiH. Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model. Curr Oncol Rep2005;7:307311.

    • Search Google Scholar
    • Export Citation
  • 183

    ChoiHCharnsangavejCFariaSC. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol2007;25:17531759.

    • Search Google Scholar
    • Export Citation
  • 184

    ShankarSvanSonnenbergEDesaiJ. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology2005;235:892898.

    • Search Google Scholar
    • Export Citation
  • 185

    Van den AbbeeleADBadawiRD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer2002;38(Suppl 5):S6065.

    • Search Google Scholar
    • Export Citation
  • 186

    Van den AbbeeleADBadawiRDClicheJP. FDG-PET as a surrogate marker for the response to Gleevec (imatinib mesylate) in patients with advanced gastrointestinal stromal tumors (GIST). J Nucl Med2003;44:24P25P.

    • Search Google Scholar
    • Export Citation
  • 187

    YoungHBaumRCremeriusU. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer1999;35:17731782.

    • Search Google Scholar
    • Export Citation
  • 188

    Van Den AbbeeleADBadawiRDManolaJ. Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IMrefractory gastrointestinal stromal tumors (GIST) as visualized by FDGPET scanning [abstract]. J Clin Oncol2004;22(Suppl 1):Abstract 3012.

    • Search Google Scholar
    • Export Citation
  • 189

    PriorJOMontemurroMOrcurtoMV. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol2009;27:439445.

    • Search Google Scholar
    • Export Citation
  • 190

    MiettinenMLasotaJSobinLH. Gastrointestinal stromal tumors of the stomach in children and young adults. Am J Surg Pathol2005;29:13731381.

    • Search Google Scholar
    • Export Citation
  • 191

    PrakashSSarranLSocciN. Gastrointestinal stromal tumors in children and young adults. J Pediatr Hematol Oncol2005;27:179187.

  • 192

    JanewayKALieglBHarlowA. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res2007;67:90849088.

    • Search Google Scholar
    • Export Citation
  • 193

    JanewayKAAlbrittonKHVan Den AbbeeleAD. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer2009;52:767771.

    • Search Google Scholar
    • Export Citation
  • 194

    StratakisCACarneyJA. The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. J Intern Med2009;266:4352.

    • Search Google Scholar
    • Export Citation
  • 195

    KleinbaumEPLazarAJTamboriniE. Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor. Int J Cancer2008;122:711718.

    • Search Google Scholar
    • Export Citation
  • 196

    AgarwalRRobsonM. Inherited predisposition to gastrointestinal stromal tumor. Hematol Oncol Clin North Am2009;23:113.

  • 197

    AntonescuCR. Gastrointestinal stromal tumor (GIST) pathogenesis, familial GIST, and animal models. Semin Diagn Pathol2006;23:6369.

  • 198

    PasiniBMcWhinneySRBeiT. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet2008;16:7988.

    • Search Google Scholar
    • Export Citation
  • 199

    HaoHXKhalimonchukOSchradersM. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science2009;325:11391142.

    • Search Google Scholar
    • Export Citation
  • 200

    MussiCSchildhausHUGronchiA. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Clin Cancer Res2008;14:45504555.

    • Search Google Scholar
    • Export Citation
  • 201

    ShinomuraYKinoshitaKTsutsuiSHirotaS. Pathophysiology, diagnosis, and treatment of gastrointestinal stromal tumors. J Gastroenterol2005;40:775780.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1309 1309 232
PDF Downloads 189 189 18
EPUB Downloads 0 0 0